|
|
Upfront Briefing
Bristol Myers got the first CELMoD across the line. Zenbexus — iberdomide, finally with a brand name — cleared FDA on accelerated approval at $29,500 a cycle, handing the Revlimid franchise an heir just as the patent cliff comes into view. Taiho and Cullinan cleared their first-line Phase 3 in EGFR exon 20 lung cancer, though the actual numbers are being held back for a conference. And the FDA published its PDUFA VIII wish list, which would cut fees for Phase 1 work done on American soil and tax the orphan-then-expand playbook. Choosing a first-in-human site just became a regulatory decision.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,799.0 |
0.7% |
13.7% |
| Nasdaq 100 |
30,084.5 |
1.2% |
19.4% |
| Russell 2000 |
3,052.9 |
0.2% |
21.7% |
| Healthcare (XLV) |
168.4 |
0.0% |
8.3% |
| Biotech (XBI) |
156.9 |
(1.6%) |
29.1% |
| Nasdaq Biotech (NBI) |
6,815.3 |
(0.9%) |
19.4% |
| Clinical Trials (BBC) |
52.4 |
(1.3%) |
39.1% |
|
- Two sector catalysts landed — FDA's accelerated approval of Bristol Myers' Zenbexus and Taiho/Cullinan's REZILIENT3 Phase 3 win — and neither lifted the complex: XBI fell 1.6% and NBI 0.9% while XLV held flat, single-name news failing to translate into sector beta on a record-close tape.
- July PPI printed unexpectedly flat on 13 August, slowing annual growth to 4.7% and easing September rate-hike bets; the S&P 500 closed at a record 7,798.98 and the Russell 2000 also set a record, with Brent down more than 2% to $87.07 as the U.S.–Iran standoff over Hormuz ran on.
- Market data: U.S. cash close Thursday, 13 August 2026.
The Big 3
|
1
|
FDA clears Zenbexus, the first CELMoD, in myeloma
|
- FDA granted accelerated approval to Bristol Myers' iberdomide, branded Zenbexus, with daratumumab and hyaluronidase-fihj plus dexamethasone for myeloma patients with at least one prior line including a proteasome inhibitor and an IMiD — reaching as early as first relapse.
- Why it matters: Approval rests on EXCALIBER-RRMM, where the ZDd triplet doubled MRD-negative complete response against DVd, 41% versus 21%, with PFS still maturing. At $29,500 a cycle Bristol Myers now has a branded CELMoD to defend a myeloma franchise walking into the Revlimid cliff, and the label reaches first relapse rather than late-line salvage. The read-through runs past BMS: this is the first cereblon-modulating degrader to clear FDA, which reprices the targeted protein degradation complex on regulatory precedent. Risk sits in the confirmatory obligation, since accelerated approval on an MRD surrogate can be pulled if PFS disappoints, and in pairing with J&J's Darzalex Faspro, which hands a competitor volume.
- Source: Endpoints
- More: FDA; Pharmacy Times
|
|
2
|
Zipalertinib clears REZILIENT3, setting up a three-way EGFR fight
|
- Zipalertinib plus platinum chemotherapy significantly improved progression-free survival against chemotherapy alone in the 285-patient Phase 3 REZILIENT3 trial in first-line EGFR exon 20 insertion NSCLC, hitting its primary endpoint at a planned interim analysis that prompted the data monitoring committee to unblind the study.
- Why it matters: Cullinan's economics are the story: $30M on a second-line approval, $100M on a first-line nod, then a 50/50 split of U.S. pretax profits with Taiho — unusually rich for a partner that isn't commercialising. The trial hit PFS at interim but no effect size was released, so magnitude waits for a conference. The 27 February 2027 PDUFA on the post-platinum NDA is the nearer catalyst. Approval turns this into a three-way fight: J&J's Rybrevant and Lazcluze grew 70% to $546M in the first half, and AstraZeneca paid $600M upfront last month for global rights to Dizal's Zegfrovy. Risk: Takeda pulled Exkivity from this same niche in 2023 after a confirmatory miss.
-
Source:
Fierce Biotech
-
More:
BioPharma Dive; BioSpace
|
| 3 | PDUFA VIII letter would reprice where you run Phase 1 |
-
FDA released its proposed PDUFA VIII commitment letter covering FY2028–2032, headlined by a 50% application-fee cut for filings carrying data from a US-run Phase 1 started after 1 October 2027, plus a new fee on non-orphan supplements to orphan-exempt applications.
-
Why it matters:
The letter does two things with money. The 50% fee cut for US-run Phase 1 work puts a price on trial geography, which matters to anyone running first-in-human studies in Australia or China on cost grounds. The second change bites harder: a fee equal to half the full application charge on the first non-orphan supplement where the original filing took an orphan exemption, taxing the orphan-first-then-expand playbook a large slice of biotech runs on. PhRMA and BIO have already argued PDUFA is the wrong lever for the America First mechanism. PDUFA VII expires September 2027, so the comment window is where this gets fought.
-
Source:
Endpoints
-
More:
RAPS
|
Everything Else that broke
- PDS Biotech discontinued the 350-patient Versatile-003 Phase 3 of Versamune HPV plus Keytruda to back its IL-12 immunocytokine PDS0301, disclosing $5.6M in cash at 30 June. — Fierce Biotech
- Karyopharm has runway only into next month, with a debt payment due in four weeks. — Fierce Pharma
- Lilly is targeting black-market demand around retatrutide as obesity demand keeps outrunning formal channels. — STAT
- Novo's CEO argued obesity is not a zero-sum market because patients want more than one option. — Fierce Pharma
- ICER said AstraZeneca's Baxfendy misses the cost-effectiveness bar after approval. — Fierce Pharma
- China's NMPA approved 60 already-marketed foreign drugs and vaccines in 2025. — BioCentury
- Overseas MDMA and psilocybin manufacturers are eyeing the potential U.S. psychedelic therapy market. — BioSpace
- Atrium highlighted ATR 1072 IND clearance and a second Bristol Myers milestone payment in Q2. — PR
- Nektar reported Q2 results, with cash and marketable securities the main balance-sheet watchpoint. — PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Sangamo's Section 363 auction closed at ~$163.55M cash — PTC at $111M for Fabry gene therapy ST-920 plus up to $100M in approval milestones, Lilly at $50M for the capsid, zinc finger and MINT platforms and prion program ST-506. — BioSpace
- Zealand sold its remaining rusfertide economics to Royalty Pharma for $100M — $50M at closing, $50M a year later — retaining a 0.25% royalty above $1.5B in sales, ahead of a Q3 PDUFA on the Takeda/Protagonist polycythemia vera drug. — Fierce Biotech
- Ovid and Takeda moved a twice-failed epilepsy asset into a Perceptive-backed NewCo. — Endpoints
- Kirin and GenerativeX formed an AI R&D collaboration; financial terms were not disclosed. — PR
VC / Private Financings
- Khartis emerged from stealth with a $95M raise to challenge Tepezza in thyroid eye disease. — BioCentury
- Aligned Marketplace raised $20M to match self-insured employers with primary care clinics. — Endpoints
IPOs / Follow-Ons
- MapLight Therapeutics (MPLT) priced a $150M PIPE — 9.2M shares at $11.38 plus 4.0M pre-funded warrants — led by new and existing institutional investors, with Morgan Stanley, Jefferies, Leerink and Stifel as placement agents; closing 14 August. — GlobeNewswire
Academic Corner - Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. — Lancet
- Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. — NEJM
- Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting. — NEJM
|
|
A first-in-class pill with a price tag, a Phase 3 that won without showing its numbers, and a fee schedule that reads like industrial policy.
— BioBucks Team
|
|
|
